Neurim Pharmaceuticals is a drug discovery and development company. Its first approved drug, Circadin® – prolonged release melatonin for insomnia, has been commercially available in the EU since October, 2007
 
  LUNDBECK, NYCOMED
 
Learn More
 
Insomnia
 
Parkinson’s disease
 
Asthma/COPD
 
 
To establish a leadership position in small molecule drug research and development, aimed at improving quality of life of the older patient. Read More
 
24 September 2007
Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck
06 July 2007
Nycomed to market Circadin® for primary insomnia
29 June 2007
An Authorisation valid throughout the European Union was issued by the EMEA for Circadin®
27 April 2007
Neurim Pharmaceuticals announce that Circadin® (prolonged-release melatonin) for Primary Insomnia is recommended for approval in the EU
26 April 2007
Summary of positive opinion for Circadin® (EMEA Press Release)
   
 
 

 
  .
   

 

UPDATE: Circadin® has been commercially available in the EU since October, 2007
Copyright © Neurim Pharmaceuticals , Inc. All rights reserved.
 
Impresser Disclaimer Legal Site map